HOBOKEN, NJ, Jan. 6 /CNW/ - Anavex Life Sciences Corp. ("Anavex",
AVXL.OB) announced today that ANAVEX 2-73 has been named 2010's "most
promising trial drug" by the editorial staff at Alzheimer's Weekly.
The publication selected the ANAVEX 2-73 trial from a field of over 100
trials that treat dementias such as Alzheimer's and following the
review of more than 10,000 articles. Staffers and clinical experts of
Alzheimer's Weekly said that Anavex stands out when scrutinized against
their key criteria for potential treatments, including small molecule
drugs, oral bioavailability, possibility for disease modification,
targeting multiple pathways, near-term availability and entering human
"It is extremely rewarding for our team to receive such significant and
independent third-party recognition for ANAVEX 2-73 and our unique
approach in Alzheimer's disease," said Dr. Cameron Durrant, Executive
Chairman of Anavex Life Sciences Corp. "The data generated from our
extensive preclinical program suggests that ANAVEX 2-73 has the
potential to be safe and well tolerated. Furthermore, it has shown
encouraging early signs of efficacy in preclinical animal studies."
The full Alzheimer's Weekly article is available here: http://www.AlzWeek.com/node/970.
ANAVEX 2-73 is the first of a new class of compounds that act through
sigma-1 receptor agonism as well as muscarinic cholinergic effects and
modulation of endoplasmic reticulum stress thought to trigger a series
of intracellular effects which modify ion channel signaling at the
Anavex has filed the regulatory submission to begin clinical studies of
ANAVEX 2-73. The Phase I study will evaluate the maximum tolerated
dose, pharmacokinetics, pharmacodynamics, safety and bioavailability of
ANAVEX 2-73. A Phase IIa study in patients with Alzheimer's disease
and Mild Cognitive Impairment, currently scheduled to commence in mid
2011, may provide efficacy data as well as further safety data.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a biopharmaceutical
company engaged in the discovery and development of novel drug
candidates for the treatment of neurological diseases and cancer. The
Anavex proprietary SIGMACEPTOR™ Discovery Platform involves the
rational design of drug compounds targeted to specific receptors
involved in the modulation of multiple cellular biochemical signaling
The SIGMACEPTOR™-N program involves the development of novel drug
candidates that target neurological and neurodegenerative diseases
(Alzheimer's disease, epilepsy, depression, pain). The company's lead
drug candidates exhibit high affinity for sigma receptors, which have
been extensively documented as potentially valuable drug targets and
have demonstrated anti-amnesic and neuroprotective properties.
Anavex is a publicly traded company under the symbol "AVXL".
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Forward-looking statements in this
press release include that ANAVEX 2-73 has the potential to be safe and
well tolerated and effective in the treatment of Alzheimer's disease;
that we will complete a Phase I and IIa study, that Phase I will
evaluate certain aspects of our drug compound; that Phase IIa is
currently scheduled to commence in mid 2011 and may provide further
efficacy and safety data, and that our drug compounds show potential
promise to combat certain diseases. Actual events or results may
differ materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery and development, which include, without limitation, the
potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, and our ability to finance development or satisfy the
rigorous regulatory requirements for new drugs. Readers are cautioned
not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements are
qualified in their entirety by this cautionary statement and Anavex
Life Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date hereof.
SOURCE Anavex Life Sciences Corp.
For further information:
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092